Browsing Category
Pharma Industry News
4720 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
How opioid reduction strategies are driving cost savings in orthopedic surgery pathways
Find out how Pacira BioSciences, Inc. is using EXPAREL data to drive opioid reduction and cost savings in Medicare orthopedic surgery pathways.
Why targeting ERK and NF-κB pathways may change Parkinson’s disease drug development
Discover how BioVie Inc. is targeting ERK and NF-κB pathways in Parkinson’s disease and what Phase 2 data could mean. Read the full analysis.
AstraZeneca Q1 2026 results: Can oncology and rare disease growth keep AZN’s 2030 ambition on track?
AstraZeneca’s growth engine is firing, but pricing pressure and launch risk still loom. Can oncology and rare disease carry AZN to 2030?
GSK’s bepirovirsen wins FDA priority review as chronic hepatitis B strategy enters decisive phase
GSK has FDA momentum in hepatitis B. The harder question is whether bepirovirsen can turn functional cure into a real market shift.
GSK trades near 2,027p as Q1 core EPS rises 9%, full-year 2026 guidance reaffirmed
GSK beat the top line and held guidance, but the harder question is whether Specialty Medicines can keep outrunning the Vaccines and General Medicines drag.
Syntara Limited raises A$8m as ASX:SNT advances amsulostat toward Phase 2b trial
Syntara has capital, catalysts, and dilution. The real question is whether amsulostat data can shift investor trust in ASX:SNT.
Lilly bets up to $2.3bn on Ajax Therapeutics to crack the resistant myelofibrosis market with a Type II JAK2 inhibitor
Lilly is paying up to $2.3B for Ajax Therapeutics' Type II JAK2 inhibitor. The real question is whether it can crack Incyte's Jakafi grip on myelofibrosis.
Seaport Therapeutics seeks $212m IPO as neuropsychiatry biotech window reopens
Seaport’s IPO tests biotech appetite before key depression data. Here’s why SPTX, PureTech, and psychiatry investors are watching.
Ligand Pharmaceuticals (LGND) to acquire XOMA Royalty (XOMA) for $739m as biotech royalty consolidation accelerates
Ligand is buying XOMA for $739 million in cash. The real story sits inside a CVR tied to a $19.7 billion Johnson and Johnson royalty fight.
PCI Pharma Services bets over $1bn on US sterile fill-finish capacity as drug supply chains localize
Drugmakers want US capacity, but sterile fill-finish remains scarce. PCI Pharma Services is betting over $1B that resilience now wins contracts.